

Archives of Plastic Surgery

Clinical significance of Hyperhomocysteinemia in Free Flap Failure- A Case Report

ABEJE B MENJETA, Tae Hyung Kim, HyungWha Jeong, Seongsu Jeong, Changsik John Pak, Hyunsuk Peter Suh, Jp Hong.

Affiliations below.

DOI: 10.1055/a-2336-0262

Please cite this article as: MENJETA A B, Kim T, Jeong H et al. Clinical significance of Hyperhomocysteinemia in Free Flap Failure- A Case Report. Archives of Plastic Surgery 2024. doi: 10.1055/a-2336-0262

Conflict of Interest: The authors declare that they have no conflict of interest.

Abstract:

Failure of a microvascular free flap remains rare, yet multiple failures can occur, particularly in the presence of hypercoagulable conditions. This case series highlights our experience with a rare hypercoagulable state: hyperhomocysteinemia.

We present two cases of patients with hyperhomocysteinemia in this report. High-dose heparinization was administered to both patients, resulting in successful salvage of one flap and failure of the other. Notably, one patient had a history of prior free flap failures. However, after correcting hyperhomocysteinemia, subsequent free flaps were successful.

In cases of detected complications, a coagulability study is warranted, and adjustments to anticoagulation treatment may be necessary. Furthermore, when a history of flap failures is evident, screening for hyperhomocysteinemia may be warranted, with correction made prior to reconstruction.

Corresponding Author:

DOCTORATE DEGREE IN MEDICINE ABEJE B MENJETA, St Paul's Hospital Millennium Medical College, Plastic Surgery, Addis Ababa, Ethiopia, abeje.brhanu@yahoo.com, abeje.brhanu@sphmmc.edu.et

Affiliations:

ABEJE B MENJETA, St Paul's Hospital Millennium Medical College, Plastic Surgery, Addis Ababa, Ethiopia

ABEJE B MENJETA, St Paul's Hospital Millennium Medical College, Plastic Surgery, Addis Ababa, Ethiopia

Tae Hyung Kim, Asan Medical Center, Department of Plastic and Reconstructive Surgery, Seoul, Korea (the Republic of)

[...]

Jp Hong, University of Ulsan, Plastic Surgery, Seoul, Korea (the Republic of)

Clinical significance of Hyperhomocysteinemia in Free Flap Failure- A Case Report

Abeje Brhanu Menjeta², MD, Hyung Hwa Jong¹, MD, Tae Hyung Kim¹, MD, Seongsu Jeong¹, MD, Changsik John Pak¹, MD, Hyunsuk Peter Suh¹, MD, PhD, Joon Pio Hong¹, MD, PhD, MMM

1 Department of Plastic and Reconstructive Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

2 Department of Surgery Division of Plastic and Reconstructive Surgery, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia

The authors have no conflict of interest in regard to this paper.

***Corresponding author;** Joon Pio Hong, M.D., Ph.D., MMM

Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea

E-mail: joonphong@amc.seoul.kr

Abstract

Failure of a microvascular free flap remains rare, yet multiple failures can occur, particularly in the presence of hypercoagulable conditions. This case series highlights our experience with a rare hypercoagulable state: hyperhomocysteinemia.

We present two cases of patients with hyperhomocysteinemia in this report. High-dose heparinization was administered to both patients, resulting in successful salvage of one flap and failure of the other. Notably, one patient had a history of prior free flap failures. However, after correcting hyperhomocysteinemia, subsequent free flaps were successful.

In cases of detected complications, a coagulability study is warranted, and adjustments to anticoagulation treatment may be necessary. Furthermore, when a history of flap failures is evident, screening for hyperhomocysteinemia may be warranted, with correction made prior to reconstruction.

Keywords: hyperhomocysteinemia, free flap failure, hypercoagulability

Introduction

Microvascular free flap failure is becoming relatively rare in high-volume centers as an anastomosis technique and the surgeon's experience accumulates with volume.¹ Nevertheless, flap complications and failures will continue to exist due to the complexity of the surgery and the multiple variables involved despite the evolved technique and experience. Failure and

complication can be single or multifactorial including hypercoagulability, infection, hypotension, malnutrition, vasopressors, type of free flap used, recipient vessels, and others.²

Hypercoagulability, often under-evaluated, is a proven risk for vascular thrombosis and poses a major threat to microvascular free tissue transfer and reconstruction.³⁻⁵ Hypercoagulability may result from various etiologies leading to an overall incidence of thrombosis and flap loss as high as 13% and 10.3% respectively.⁵ One possible cause may be hyperhomocysteinemia which is rarely reported in literature in regards to free flap failures. Homocysteine physiological levels are commonly considered normal between 5 and 15 $\mu\text{mol/l}$, while hyperhomocysteinemia is considered mild when ranging from 15 to 30 $\mu\text{mol/l}$, intermediate for values between 30 and 100 $\mu\text{mol/l}$, and serious for values exceeding 100 $\mu\text{mol/l}$.⁶ Hyperhomocysteinemia in a mild form is approximated to be found in 5–7% of the general population and 40% in patients with vascular disease.⁷ Increasing evidence is suggesting that hyperhomocysteinemia is closely related to venous thrombosis, peripheral vascular diseases, coronary artery disease, myocardial infarction, and stroke.⁶⁻⁸ It has also been reported that lowering a patient's homocysteine levels by 25% decreases stroke risk by 19%.⁸

Despite the increasing evidence on hypercoagulopathy, little has been studied or reported regarding the possible effects of hyperhomocysteinemia on microvascular reconstruction.² In this study, the authors will present work on identifying the incidence, establishing hyperhomocysteinemia as a possible risk factor for flap complication, and providing insights on the management of such a condition.

Case reports

A retrospective chart review was conducted from December 1st, 2021, to December 1st, 2022, revealing two cases of hyperhomocysteinemia patients. Patient consent forms were obtained for the use of photographs and information in the study.

Case 1

A 39-year-old male patient presented with an open tibiofibular fracture in his left leg, accompanied by a soft tissue defect, seven months post-initial injury. Despite three prior failed attempts at free flap reconstruction (two Anterolateral Thigh [ALT] flaps and one Thoracodorsal Artery Perforator [TDAP] flap), the patient's condition worsened, manifesting as a necrotic flap covering the anterior middle third of the left leg, equinus deformity, and restricted knee joint motion (Figure 1). Notably, the patient had no comorbidities, with three major arteries intact, but exhibited elevated homocysteine levels ($42.1\mu\text{mol/L}$) on coagulation studies (Figure 1).

Given the unsuccessful previous attempts, postoperative heparin infusion was planned following consultation with hematology. Reconstruction was attempted using a SCIP free flap connected end-to-side on the anterior tibial artery (ATA) and end-to-end on the accompanying vein. Unfortunately, signs of flap distress emerged on the first day, necessitating exploration. Thrombosis was discovered in both the artery and vein, prompting thrombectomy, irrigation with heparin, and re-anastomosis. Despite these interventions, flap perfusion weakened within 30 minutes, and further thrombosis occurred, prompting a change in the recipient pedicle to the posterior tibial artery and vein using vein grafts. However, thrombosis recurred in the vein graft despite intensive heparinization. Consequently, the free flap was abandoned, and a skin graft harvested from the SCIP flap was applied over the defect (Figure 1(C)), with negative pressure wound therapy employed.

Subsequent intervention focused on normalizing the elevated homocysteine level through folate and vitamin B12 supplementation, resulting in a reduction to 14.1 μ mol/L over four months. A second attempt at free flap reconstruction using the Medial Sural Artery Perforator (MSAP) technique on the anterior tibial artery and accompanying vein proved successful, without complications (Figure 1(D)).

Case 2

A 29-year-old male patient presented to our hospital seventeen months after sustaining a road traffic accident, resulting in an open distal tibiofibular fracture and a soft tissue defect on his left ankle. He had no history of diabetes or hypertension but had previously undergone a failed Anterolateral Thigh (ALT) free flap reconstruction, performed one month after the accident. On examination, an open wound was observed on the medial side of the left ankle, with exposed bone and serous discharge (Figure 2). Further investigation revealed a comminuted fracture with chronic osteomyelitis and non-union of the left distal tibiofibular region, confirmed by bone spectroscopy. Additionally, his coagulation profile showed an elevated serum homocysteine level of 26.8 μ mol/L.

To address the chronic osteomyelitis and soft tissue complications, a gracilis muscle flap (13cmx6cm) based on the medial circumflex femoral artery (MCFA) and accompanying vein was performed. The posterior tibial artery and accompanying vein were utilized as recipient vessels, with an interposition vein graft harvested from the great saphenous vein. Despite successful microvascular anastomosis of one vein and one artery to the posterior tibial artery (PTA), flap congestion was noted on the same day, necessitating a return to the operating

room. A non-functional venous anastomosis was identified, leading to irrigation with heparin followed by microanastomosis revision using another vein graft.

Unfortunately, non-reassuring flap monitoring outcomes on the first postoperative day prompted further revision, revealing a clot in the artery and kinking of the vein graft. The vein grafts were excised, and one vein and one artery were re-anastomosed, with aggressive heparinization initiated. The wound at the revision site was closed primarily, and the ankle was splinted at 90 degrees. Heparinization was continued for two weeks.

By the third postoperative week, heparinization was tapered based on coagulation profile results. The gracilis muscle flap was then covered with split-thickness skin grafts. At the fifth postoperative week, the patient attended an outpatient appointment, where a well-taken muscle flap and split-thickness skin graft on the medial aspect of the left ankle were observed. Partial weight-bearing was permitted based on these findings, and the patient was scheduled for subsequent follow-up appointments.

Discussion

Hyperhomocysteinemia has been implicated in various health conditions, including hypercoagulability, thromboembolism, peripheral vascular diseases, coronary artery disease, myocardial infarction, and stroke, as evidenced by epidemiological studies.²

Homocysteine, a sulfhydryl-containing amino acid, is derived from the metabolism of methionine, an essential amino acid. In healthy individuals, excess homocysteine in the

bloodstream is typically metabolized via either a remethylation pathway to methionine or a trans-sulfuration pathway to cysteine.⁹ However, when these metabolic pathways are impaired, excess homocysteine can undergo auto-oxidation, leading to the formation of biologically reactive products that induce cellular toxicity and contribute to blood clot formation in arteries and veins.⁹ The plasma level of homocysteine is influenced by both genetic and environmental factors. Genetic defects in genes encoding enzymes such as Methyltetrahydrofolate reductase and Methionine synthase can cause hyperhomocysteinemia. Additionally, environmental factors such as dietary deficiencies of vitamin B12, B6, and folate, as well as impaired renal function, can elevate plasma homocysteine levels.⁹⁻¹¹ Consequently, treatment often involves supplementation with vitamin B and folic acid. In cases where multiple flap attempts failed despite immediate post-anastomosis high-dose heparin treatment, a similar protocol using vitamin B and folic acid supplementation for four months successfully normalized homocysteine levels. This normalization ultimately led to a successful outcome after microsurgery.

Hyperhomocysteinemia is diagnosed when plasma homocysteine levels exceed 15 $\mu\text{mol/L}$, with phenotypes varying depending on severity: mild (15 to 24 $\mu\text{mol/L}$), moderate (25 to 100 $\mu\text{mol/L}$), or severe (>100 $\mu\text{mol/L}$). The average normal plasma homocysteine level is approximately 10 $\mu\text{mol/L}$.¹² Mild hyperhomocysteinemia is estimated to affect 5–7% of the general population globally and up to 40% of patients with vascular disease. Smoking and betel nut use have been associated with a higher prevalence of hyperhomocysteinemia.¹³⁻¹⁸

The incidence of mild hyperhomocysteinemia in this series was approximately 2% (3 out of 126 cases), lower than the general population rate of 5–7%.⁷ Despite this, even a 2% incidence rate still poses a potential risk for complications after free flap surgeries. The authors initially overlooked the possibility of hyperhomocysteinemia as a high-risk factor for thrombosis and did not consider preoperative correction. In this report, we present three cases of patients with elevated homocysteine levels (Table 1).

Coagulation index studies post-complication often appear normal and do not indicate any hypercoagulative factor. However, our study suggests a significant subset of patients with hyperhomocysteinemia, strongly associated with post-microsurgery complications, warranting the inclusion of homocysteine level evaluation in coagulation index studies. Additionally, when dealing with patients who have experienced previous flap failures or thrombotic episodes, obtaining preoperative homocysteine level studies may elucidate reasons for failure and allow for corrective measures to prevent further complications. Of the three patients with hyperhomocysteinemia in our series, two had experienced prior failures.

For patients diagnosed with hyperhomocysteinemia, anticoagulant medications such as aspirin, clopidogrel, heparin, and warfarin are recommended to prevent blood clots and treat microvascular thrombosis.^{2,9} In two of the three patients with hyperhomocysteinemia, high-dose heparin was successful in providing adequate circulation, leading to successful flap outcomes. Our protocol includes a 5,000 IU bolus of heparin followed by continuous infusion of heparinized saline solution (500ml of NS with 20,000 IU of heparin) at a rate of 2cc/hour, targeting an aPTT level of 60-80 for 2 weeks post-surgery. Adjustments to the infusion rate are made based on aPTT levels. However, one patient with an intermediate level of 42.1 μ mol/L did not respond to heparin and experienced failure. Further research is needed to determine the optimal heparin dosage based on the severity of hyperhomocysteinemia-induced thrombosis and to develop an algorithm for flap complications related to hyperhomocysteinemia.

Several treatment options are globally recognized and readily available for hyperhomocysteinemia, including folic acid, vitamin B12, and pyridoxine. Studies have shown that folic acid or pyridoxine alone can reduce plasma homocysteine levels by 22%, while administering both together can lead to a 38.5% reduction. Vitamin B12 alone can result in an 11% reduction in plasma homocysteine levels.¹⁹ Randomized clinical trials have demonstrated a significant decrease in plasma homocysteine levels with oral supplementation of a combination of folic acid, vitamin B6, and vitamin B12.²⁰ Research has also

shown that a one-month treatment of hyperhomocysteinemia with pyridoxine (600 mg/day) and folic acid (10 mg/day) can partially reduce homocysteine levels.²¹ Small doses of folate (0.4–5 mg/day), vitamin B12 (400 µg/day), and vitamin B6 (10–50 mg/day) have been suggested to rapidly decrease plasma homocysteine concentration. Furthermore, a combination supplementation of folic acid (25 mg), vitamin B6 (25 mg), and vitamin B12 (250 µg/day) has been associated with a reduction in atherosclerosis, as evidenced by decreased carotid plaque.

It's important to note that the timing of these treatments in relation to meals is crucial. Pyridoxine is most effective when taken after a meal, while folic acid and vitamin B12 primarily act under fasting conditions. Adjusting the timing of intake accordingly is necessary for optimal efficacy.²²

Conclusion

When complications arise during free flap monitoring, it is essential to conduct a coagulability study and adjust anticoagulation treatment accordingly. Additionally, in cases where a history of flap failures is evident, screening for hyperhomocysteinemia may be necessary, with corrections made before proceeding with reconstruction.

References

1. Baumeister S, Follmar KE, Zenn MR, Erdmann D, Levin LS. Strategy for reoperative free flaps after failure of a first flap. *Plast Reconstr Surg* 2008;122(3):962-971
2. Biben JA, Atmodiwirjo P. Free flap thrombosis in patients with hypercoagulability: A systematic review. *Arch Plast Surg* 2019;46(6):572-579
3. Khouri RK. Avoiding free flap failure. *Clin Plast Surg* 1992;19(4):773-781
4. Masoomi H, Clark EG, Paydar KZ, et al. Predictive risk factors of free flap thrombosis in breast reconstruction surgery. *Microsurgery* 2014;34(8):589-594
5. Pannucci CJ, Kovach SJ, Cuker A. Microsurgery and the Hypercoagulable State: A Hematologist's Perspective. *Plast Reconstr Surg* 2015;136(4):545e-552e
6. Tinelli C, Di Pino A, Ficulle E, Marcelli S, Feligioni M. Hyperhomocysteinemia as a Risk Factor and Potential Nutraceutical Target for Certain Pathologies. *Front Nutr* 2019;649
7. Park WC, Chang JH. Clinical Implications of Methylenetetrahydrofolate Reductase Mutations and Plasma Homocysteine Levels in Patients with Thromboembolic Occlusion. *Vasc Specialist Int* 2014;30(4):113-119
8. Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: a meta-analysis. *Stroke* 2010;41(6):1205-1212
9. Blom HJ, Smulders Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. *J Inherit Metab Dis* 2011;34(1):75-81
10. Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. *Circulation* 2011;123(16):1763-1770
11. Bostom AG, Shemin D, Gohh RY, et al. Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. *Transplantation* 2000;69(10):2128-2131

12. Bright A, Devi TR, Gunasekaran S. Plasma Homocysteine Levels And Efficacy Of Vitamin Supplementation Among Patients With Atherosclerosis—A Spectral And Clinical Follow Up. *Int J Pharma Bio Sci* 2011;2(3):346-354.
13. Tagliari B, Zamin LL, Salbego CG, Netto CA, Wyse AT. Hyperhomocysteinemia increases damage on brain slices exposed to in vitro model of oxygen and glucose deprivation: prevention by folic acid. *Int J Dev Neurosc* 2006;24(4):285-291.
14. Auer J, Berent R, Eber B. Homocysteine and risk of cardiovascular disease. *J Clinic and Basic Cardio* 2001;4(4):261-264.
15. Yap S. Classical homocystinuria: vascular risk and its prevention. *J Inherit Metab Dis* 2003;26(2-3):259-65.
16. Jameson JL, Kasper DL, Fauci AS, Hauser SL, Longo DL, Loscalzo J. *Harrison's principles of internal medicine*. 15th ed. New York: McGraw-Hill; 2018. 2301–2309p.
17. Harmon DL, Woodside JV, Yarnell JWG, et al. The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinemia. *QJM* 1996;89(8):571-578.
18. Thomas RH. Hypercoagulability syndromes. *Arch Intern Med* 2001;161(20):2433-2439.
19. Lobo CA, Millward SF. Homocystinuria: A cause of hypercoagulability that may be unrecognized. *J Vasc Interv Radiol* 1998;9(6):971-975.
20. Sato Y, Kaji M, Kondo I, Yoshida H, Satoh K, Metoki N. Hyperhomocysteinemia in Japanese patients with convalescent stage ischemic stroke: effect of combined therapy with folic acid and mecobalamine. *J Neurol Sci* 2002;202(1-2):65-68.
21. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. *JAMA* 2004;291(5):565-575.

22. Montero Brens C, Dalmau Serra J, Cabello Tomás ML, García Gómez AM, Rodes Monegal M, Vilaseca Busca A. Homocistinuria: eficacia del tratamiento con piridoxina, ácido fólico y betaína [Homocystinuria: effectiveness of the treatment with pyridoxine, folic acid, and betaine]. *An Esp Pediatr* 1993 Jul;39(1):37-41.

Figure 1. (A) Initial photograph of the case report during the initial evaluation at our center (B) Conventional angiography of the case report (C) Post-op 2nd-week picture of the case report after failed SCIP free flap (D) Post-op 2nd-month picture of the case report following MSAP free flap

Figure 2. (A) Initial photograph of the patient presenting a skin defect with exposed bone due to chronic osteomyelitis (B) Bone (left) & WBC (right) SPECT/CT imaging of the patient demonstrates a non-union in the left distal tibia, characterized by diffusely increased tracer uptake, sclerotic changes, and WBC accumulation around a comminuted fracture with a dislodged screw, suggestive of probable osteomyelitis (C) Photograph taken on the 5th postoperative day after gracilis muscle flap reconstruction in the patient with chronic osteomyelitis and a history of free flap failure. (D) The application of a skin graft following stabilization of the free flap.

Table 1. List of cases with an early free flap complication in patients with hyperhomocysteinemia

Table 1. List of cases with an early free flap complication in patients with hyperhomocysteinemia

No .	Age	Sex	Free flap Type	Type of free flap complication	Homocysteine level at the time of failure	Total attempt of failures
1	39y	M	SCIP	Venous thrombosis	42.1 μ mol/L \uparrow	4
2	30y	M	Gracilis	AV thrombosis	26.8 μ mol/L \uparrow	1
3	29y	M	SCIP	Arterial occlusion	25.8 μ mol/L \uparrow	0

SCIP: Superficial circumflex iliac artery perforator fl

